title: Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): A review.
abstract: The treatment paradigm for nonmelanoma skin cancer remains surgical. This fact combined with its remarkably high incidence positions it as the fifth most costly cancer to treat in the Medicare population. To address this, consideration of alternative medical therapeutics is warranted. Intralesional 5-fluorouracil is a potentially affordable option that may demand further investigation. This literature review examines current data on its efficacy and adverse effects.
authors.affiliation: University of South Florida College of Medicine, Tampa, Florida.
authors.forename: Lauren
authors.initials: L
authors.lastname: Metterle
authors.affiliation: University of South Florida College of Medicine, Tampa, Florida.
authors.forename: Christopher
authors.initials: C
authors.lastname: Nelson
authors.affiliation: University of South Florida College of Medicine, Tampa, Florida. Electronic address: nishitpatelmd@gmail.com.
authors.forename: Nishit
authors.initials: N
authors.lastname: Patel
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil
keywords: 5-fluorouracil; basal cell carcinoma; intralesional; management; medical therapy; nonmelanoma skin cancer; squamous cell carcinoma